A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters.

Slides:

Advertisements

Similar presentations

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

Advertisements

Clinical Outcomes with Newer Antihyperglycemic Agents FDA-Mandated CV Safety Trials 1.

Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Effects of Habitual Coffee Consumption on Cardiometabolic.

Clinical Outcomes with Newer Antihyperglycemic Agents

The SPRINT Research Group

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2012 American Medical Association. All rights reserved.

Risk of Heart Failure Among Postmenopausal WomenCLINICAL PERSPECTIVE

A: Kaplan-Meier estimate of time to first LLA

Impact of Electronic Acute Kidney Injury (AKI) Alerts With Automated Nephrologist Consultation on Detection and Severity of AKI: A Quality Improvement.

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Selected efficacy and safety parameters.

Further exploration of the risk factor associations with either the first or subsequent congestive heart failure (CHF) events using the Prentice, Williams,

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Composite of complications including cardiovascular (CV): acute myocardial infarction, cardiac arrhythmia requiring medical treatment and heart failure;

Yousef Rezaei, MD American Journal of Kidney Diseases

Volume 91, Issue 1, Pages (January 2017)

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Cumulative incidences of events, according to glucose-control strategy

Toshiaki Toyota et al. JCIN 2017;10:27-37

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Kaplan-Meier plots of hHF: DPP-4i and SU cohort with baseline CVD (panel A); saxagliptin and sitagliptin cohorts with baseline CVD (panel B); DPP-4i and.

Baseline Characteristics by hs-CRP

Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Svend A. Mortensen et al. JCHF 2014;2:

Keratinocyte growth factor (KGF) versus no KGF for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic.

T2DM patients with HF may benefit from SGLT2 inhibitor therapy

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Relationship between selected metabolic parameters and the primary composite end point. Relationship between selected metabolic parameters and the primary.

EMPA-REG OUTCOME: Cumulative incidence of the primary outcome

Relative effects of glucose-control strategy on microvascular disease.

—ROC curves for each simple test compared with NCS (gold standard) plotting the sensitivity versus 1-specificity (the false-positive rate) for different.

Associations between type of MI and incident HF

An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61

Saxagliptin improves glycemic control in younger and older individuals with type 2 diabetes. Saxagliptin improves glycemic control in younger and older.

HRs for prostate cancer by medication status.

Pooled risk with 95% CI of ACM (A) and CVD risk (B) for the highest vs

The possible off-target effect of increased heart failure hospitalizations from saxagliptin in the SAVOR trial. The possible off-target effect of increased.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Atrasentan reduces albuminuria in diabetic apoE KO mice.

Baseline predictors of acute complication of diabetes among immigrants with language barriers (N = 87,707). *Adjustment for all variables listed, as well.

Baseline predictors for risk of cardiovascular events or all-cause mortality among immigrants with language barriers (N = 87,707). *Adjustment for all.

Multivariate-adjusted HRs (95% CI) for deaths from CV disease (CVD), coronary heart disease (CHD), stroke, and all-cause mortality according to fasting.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Forest plot and pooled estimates of the effect of NAFLD on the risk of incident diabetes in 16 eligible studies, stratified by length of follow-up (FU)

Increase of physical activity over time associated with lower HF risk

Effect of empagliflozin on efficacy parameters at week 18.

Effect of randomized treatment on all renal events (top) and the composite of all renal events, macrovascular events, or all-cause mortality (bottom) according.

Glycemic control and body weight over 52 weeks.

Median (interquartile range) of sensor glucose (A) and insulin delivery (B) during closed-loop (solid red line and red shaded area) and control period.

ROC curves for cardiovascular events, all-cause mortality, and disease progression. ROC curves for cardiovascular events, all-cause mortality, and disease.

Improvements in physical function.

A: Forest plot of Peto odds ratios (ORs) of main glycemic end points, as defined in each trial, from published RCTs of bariatric/metabolic surgery compared.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Correlations among chronic kidney disease (CKD) classification, urinary adiponectin level, eGFR, and ACR. (A) Correlation between CKD classification and.

Cryotherapy versus no cryotherapy for the reduction of severe oral mucositis in patients receiving treatment for cancer or undergoing haematopoietic stem.

Gianluigi Savarese et al. JCHF 2016;4:

Visualization of prescriptive algorithm: provider dashboard prototype.

One-year cumulative incidence rates of adverse clinical outcomes in 9,428 outpatients with CHF stratified by diabetes status at baseline. One-year cumulative.

Association of body mass index with all-cause mortality in diabetes and non-diabetes populations, by smoking status. Association of body mass index with.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Correlation between urinary albumin excretion rate and expression of platelet surface markers, active GPIIb/IIIa, and P-selectin. Correlation between urinary.

Incidences of transitions between glycemic states by 25-OHD level.

OR for cerebral infarction in groups stratified on the basis of “unfavorable” proatherothrombotic alleles. OR for cerebral infarction in groups stratified.

Causal diagrams that represent three possible relationships between smoking, ESRD, and albumin-to-creatinine ratio (ACR) in the Study of Heart and Renal.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Changes in urinary albumin excretion rate in relation to baseline (top), cross-sectional values of GFR (middle), and MABP (bottom) during treatment with.

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Presentation transcript:

A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters. A: Forest plot of the HR of AE of bone fracture between the saxagliptin and placebo groups across subgroups by demographic and medical history parameters. Forest plot of the HR of the time to first event for bone fracture (derived from CRF or Preferred Terms) by baseline CV risk, renal function strata, and demographic subgroups (B) by demographic subgroups (C), and by baseline diabetic medications (DM) (D) in the ITT population. ACR, albumin-to-creatinine ratio; CHF, congestive heart failure; MRF, multiple risk factors. The solid squares denote the mean difference and are proportional to the weights used, the horizontal lines represent the 95% CIs, and the vertical line indicates no effect. Ofri Mosenzon et al. Dia Care 2015;38:2142-2150 ©2015 by American Diabetes Association